Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay

Jason J. LeBlanc; May ElSherif; Lingyun Ye; Donna MacKinnon-Cameron; Ardith Ambrose; Todd F. Hatchette; Amanda L.S. Lang; Hayley D. Gillis; Irene Martin; Walter H.B. Demczuk; Melissa K. Andrew; Guy Boivin; William Bowie; Karen Green; Jennie Johnstone; Mark Loeb; Anne E. McCarthy; Allison McGeer; Makeda Semret; Sylvie Trottier; Louis Valiquette; Duncan Webster; Shelly A. McNeil

doi:10.1016/j.vaccine.2022.02.081

Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay

Jason J. LeBlanc, May ElSherif, Lingyun Ye, Donna MacKinnon-Cameron, Ardith Ambrose, Todd F. Hatchette, Amanda L.S. Lang, Hayley D. Gillis, Irene Martin, Walter H.B. Demczuk, Melissa K. Andrew, Guy Boivin, William Bowie, Karen Green, Jennie Johnstone, Mark Loeb, Anne E. McCarthy, Allison McGeer, Makeda Semret, Sylvie TrottierLouis Valiquette, Duncan Webster, Shelly A. McNeil

Medicine

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

8 Citas (Scopus)

Resumen

Objective(s): In the context of age- and risk-based pneumococcal vaccine recommendations in Canada, this study presents updated data from active surveillance of pneumococcal community acquired pneumonia (pCAP) and invasive pneumococcal disease (IPD) in hospitalized adults from 2010 to 2017. Methods: S. pneumoniae was detected using culture (blood and sputum), and urine antigen detection (UAD). Serotyping was performed with Quellung, PCR, or using the PCV13- and PPV23 (non-PCV13)-specific UADs. Laboratory results, demographic, and outcome data were categorized by age (16–49, 50–64, and 65 + ) and by disease [non-bacteremic pCAP, bacteremic pCAP, and IPD(non-CAP)]. Results: 11,129 CAP cases and 216 cases of IPD (non-CAP) were identified. Laboratory testing for S. pneumoniae was performed in 8912 CAP cases, identifying 1264 (14.2%) as pCAP. Of pCAP cases, 811 (64.1%) were non-bacteremic and 455 (35.9%) were bacteremic. Adults 65 + years represented 54.5% of non-bacteremic pCAP, 41.4% of bacteremic pCAP, and 48.6% of IPD cases. Adults 50–64 years contributed 30.3%, 33.1%, and 29.9%, respectively. In pCAP, PCV13 serotypes declined between 2010 and 2014 due to declines in serotypes 7F and 19A, then plateaued from 2015 to 2017 with persistence of serotype 3. In later study years, non-bacteremic pCAP was predominant, and PPV23 (non-PCV13) serotypes increased from 2015 to 2017, with serotypes 22F, 11A, and 9 N being most frequently identified. Compared to non-pCAP, pCAP cases were more likely to be admitted to intensive care units and require mechanical ventilation. These outcomes and mortality were more common in bacteremic pCAP and IPD, versus non-bacteremic pCAP. Conclusion(s): Along with IPD, pCAP surveillance (bacteremic and non-bacteremic) is important as their trends may differ over time. With insufficient herd protection from PCV13 childhood immunization, or use of PPV23 in adults, this study supports direct adult immunization with PCV13 or higher valency conjugate vaccines to reduce the residual burden of pCAP and IPD.

Idioma original	English
Páginas (desde-hasta)	2635-2646
Número de páginas	12
Publicación	Vaccine
Volumen	40
N.º	18
DOI	https://doi.org/10.1016/j.vaccine.2022.02.081
Estado	Published - abr. 20 2022

Nota bibliográfica

Funding Information:
This work was supported by the Public Health Agency of Canada (PHAC), the Canadian Institutes of Health Research (CIHR), and by an investigator-initiated research grant to CIRN from Pfizer Canada. The authors would like to thank all CIRN SOS surveillance monitors, as well as staff at the Canadian Center for Vaccinology (CCfV), who were instrumental in the recruitment, collection, and processing of CAP and IPD specimens. Technical assistance of the laboratory staff at the Streptococcus and Sexual Transmitted Diseases Unit of the National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC) was greatly appreciated. The authors are indebted to Pfizer Laboratories for providing access to UAD-1 and UAD-2 testing.

Funding Information:
SAM received research grants from Pfizer supporting this investigator-initiated study, as well as other from GlaxoSmithKline (GSK) and Sanofi Pasteur; All authors participated on the investigator-initiated grants sponsored by Pfizer and JL and TH declare similar participating for studies sponsored by GSK; JL received research grants from Merck; LV received research grants from GSK, Pfizer, Optimer, Cubist and Merck, and personal fees from Merck, Optimer and Cubist. ML received grants from Pfizer. MKA reports grant funding from GSK and Sanofi and honoraria from Sanofi, Seqirus and Pfizer. No other conflicts were declared.

Funding Information:
This work was supported by the Public Health Agency of Canada (PHAC), the Canadian Institutes of Health Research (CIHR), and by an investigator-initiated research grant to CIRN from Pfizer Canada. The authors would like to thank all CIRN SOS surveillance monitors, as well as staff at the Canadian Center for Vaccinology (CCfV), who were instrumental in the recruitment, collection, and processing of CAP and IPD specimens. Technical assistance of the laboratory staff at the Streptococcus and Sexual Transmitted Diseases Unit of the National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC) was greatly appreciated. The authors are indebted to Pfizer Laboratories for providing access to UAD-1 and UAD-2 testing.

Publisher Copyright:
© 2022 The Author(s)

ASJC Scopus Subject Areas

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

PubMed: MeSH publication types

Journal Article
Research Support, Non-U.S. Gov't

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.1016/j.vaccine.2022.02.081

Otros archivos y enlaces

Huella

Profundice en los temas de investigación de 'Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay'. En conjunto forman una huella única.

Citar esto

LeBlanc, J. J., ElSherif, M., Ye, L., MacKinnon-Cameron, D., Ambrose, A., Hatchette, T. F., Lang, A. L. S., Gillis, H. D., Martin, I., Demczuk, W. H. B., Andrew, M. K., Boivin, G., Bowie, W., Green, K., Johnstone, J., Loeb, M., McCarthy, A. E., McGeer, A., Semret, M., ... McNeil, S. A. (2022). Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. Vaccine, 40(18), 2635-2646. https://doi.org/10.1016/j.vaccine.2022.02.081

Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. / LeBlanc, Jason J.; ElSherif, May; Ye, Lingyun et al.
En: Vaccine, Vol. 40, N.º 18, 20.04.2022, p. 2635-2646.

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

LeBlanc, JJ, ElSherif, M, Ye, L, MacKinnon-Cameron, D, Ambrose, A, Hatchette, TF, Lang, ALS, Gillis, HD, Martin, I, Demczuk, WHB, Andrew, MK, Boivin, G, Bowie, W, Green, K, Johnstone, J, Loeb, M, McCarthy, AE, McGeer, A, Semret, M, Trottier, S, Valiquette, L, Webster, D & McNeil, SA 2022, 'Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay', Vaccine, vol. 40, n.º 18, pp. 2635-2646. https://doi.org/10.1016/j.vaccine.2022.02.081

LeBlanc JJ, ElSherif M, Ye L, MacKinnon-Cameron D, Ambrose A, Hatchette TF et al. Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay. Vaccine. 2022 abr. 20;40(18):2635-2646. doi: 10.1016/j.vaccine.2022.02.081

@article{c783f9c6aa2747bea9bf0db3c33f87c3,

title = "Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay",

abstract = "Objective(s): In the context of age- and risk-based pneumococcal vaccine recommendations in Canada, this study presents updated data from active surveillance of pneumococcal community acquired pneumonia (pCAP) and invasive pneumococcal disease (IPD) in hospitalized adults from 2010 to 2017. Methods: S. pneumoniae was detected using culture (blood and sputum), and urine antigen detection (UAD). Serotyping was performed with Quellung, PCR, or using the PCV13- and PPV23 (non-PCV13)-specific UADs. Laboratory results, demographic, and outcome data were categorized by age (16–49, 50–64, and 65 + ) and by disease [non-bacteremic pCAP, bacteremic pCAP, and IPD(non-CAP)]. Results: 11,129 CAP cases and 216 cases of IPD (non-CAP) were identified. Laboratory testing for S. pneumoniae was performed in 8912 CAP cases, identifying 1264 (14.2%) as pCAP. Of pCAP cases, 811 (64.1%) were non-bacteremic and 455 (35.9%) were bacteremic. Adults 65 + years represented 54.5% of non-bacteremic pCAP, 41.4% of bacteremic pCAP, and 48.6% of IPD cases. Adults 50–64 years contributed 30.3%, 33.1%, and 29.9%, respectively. In pCAP, PCV13 serotypes declined between 2010 and 2014 due to declines in serotypes 7F and 19A, then plateaued from 2015 to 2017 with persistence of serotype 3. In later study years, non-bacteremic pCAP was predominant, and PPV23 (non-PCV13) serotypes increased from 2015 to 2017, with serotypes 22F, 11A, and 9 N being most frequently identified. Compared to non-pCAP, pCAP cases were more likely to be admitted to intensive care units and require mechanical ventilation. These outcomes and mortality were more common in bacteremic pCAP and IPD, versus non-bacteremic pCAP. Conclusion(s): Along with IPD, pCAP surveillance (bacteremic and non-bacteremic) is important as their trends may differ over time. With insufficient herd protection from PCV13 childhood immunization, or use of PPV23 in adults, this study supports direct adult immunization with PCV13 or higher valency conjugate vaccines to reduce the residual burden of pCAP and IPD.",

author = "LeBlanc, {Jason J.} and May ElSherif and Lingyun Ye and Donna MacKinnon-Cameron and Ardith Ambrose and Hatchette, {Todd F.} and Lang, {Amanda L.S.} and Gillis, {Hayley D.} and Irene Martin and Demczuk, {Walter H.B.} and Andrew, {Melissa K.} and Guy Boivin and William Bowie and Karen Green and Jennie Johnstone and Mark Loeb and McCarthy, {Anne E.} and Allison McGeer and Makeda Semret and Sylvie Trottier and Louis Valiquette and Duncan Webster and McNeil, {Shelly A.}",

note = "Funding Information: This work was supported by the Public Health Agency of Canada (PHAC), the Canadian Institutes of Health Research (CIHR), and by an investigator-initiated research grant to CIRN from Pfizer Canada. The authors would like to thank all CIRN SOS surveillance monitors, as well as staff at the Canadian Center for Vaccinology (CCfV), who were instrumental in the recruitment, collection, and processing of CAP and IPD specimens. Technical assistance of the laboratory staff at the Streptococcus and Sexual Transmitted Diseases Unit of the National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC) was greatly appreciated. The authors are indebted to Pfizer Laboratories for providing access to UAD-1 and UAD-2 testing. Funding Information: SAM received research grants from Pfizer supporting this investigator-initiated study, as well as other from GlaxoSmithKline (GSK) and Sanofi Pasteur; All authors participated on the investigator-initiated grants sponsored by Pfizer and JL and TH declare similar participating for studies sponsored by GSK; JL received research grants from Merck; LV received research grants from GSK, Pfizer, Optimer, Cubist and Merck, and personal fees from Merck, Optimer and Cubist. ML received grants from Pfizer. MKA reports grant funding from GSK and Sanofi and honoraria from Sanofi, Seqirus and Pfizer. No other conflicts were declared. Funding Information: This work was supported by the Public Health Agency of Canada (PHAC), the Canadian Institutes of Health Research (CIHR), and by an investigator-initiated research grant to CIRN from Pfizer Canada. The authors would like to thank all CIRN SOS surveillance monitors, as well as staff at the Canadian Center for Vaccinology (CCfV), who were instrumental in the recruitment, collection, and processing of CAP and IPD specimens. Technical assistance of the laboratory staff at the Streptococcus and Sexual Transmitted Diseases Unit of the National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC) was greatly appreciated. The authors are indebted to Pfizer Laboratories for providing access to UAD-1 and UAD-2 testing. Publisher Copyright: {\textcopyright} 2022 The Author(s)",

year = "2022",

month = apr,

day = "20",

doi = "10.1016/j.vaccine.2022.02.081",

language = "English",

volume = "40",

pages = "2635--2646",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "18",

}

TY - JOUR

T1 - Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay

AU - LeBlanc, Jason J.

AU - ElSherif, May

AU - Ye, Lingyun

AU - MacKinnon-Cameron, Donna

AU - Ambrose, Ardith

AU - Hatchette, Todd F.

AU - Lang, Amanda L.S.

AU - Gillis, Hayley D.

AU - Martin, Irene

AU - Demczuk, Walter H.B.

AU - Andrew, Melissa K.

AU - Boivin, Guy

AU - Bowie, William

AU - Green, Karen

AU - Johnstone, Jennie

AU - Loeb, Mark

AU - McCarthy, Anne E.

AU - McGeer, Allison

AU - Semret, Makeda

AU - Trottier, Sylvie

AU - Valiquette, Louis

AU - Webster, Duncan

AU - McNeil, Shelly A.

N1 - Funding Information: This work was supported by the Public Health Agency of Canada (PHAC), the Canadian Institutes of Health Research (CIHR), and by an investigator-initiated research grant to CIRN from Pfizer Canada. The authors would like to thank all CIRN SOS surveillance monitors, as well as staff at the Canadian Center for Vaccinology (CCfV), who were instrumental in the recruitment, collection, and processing of CAP and IPD specimens. Technical assistance of the laboratory staff at the Streptococcus and Sexual Transmitted Diseases Unit of the National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC) was greatly appreciated. The authors are indebted to Pfizer Laboratories for providing access to UAD-1 and UAD-2 testing. Funding Information: SAM received research grants from Pfizer supporting this investigator-initiated study, as well as other from GlaxoSmithKline (GSK) and Sanofi Pasteur; All authors participated on the investigator-initiated grants sponsored by Pfizer and JL and TH declare similar participating for studies sponsored by GSK; JL received research grants from Merck; LV received research grants from GSK, Pfizer, Optimer, Cubist and Merck, and personal fees from Merck, Optimer and Cubist. ML received grants from Pfizer. MKA reports grant funding from GSK and Sanofi and honoraria from Sanofi, Seqirus and Pfizer. No other conflicts were declared. Funding Information: This work was supported by the Public Health Agency of Canada (PHAC), the Canadian Institutes of Health Research (CIHR), and by an investigator-initiated research grant to CIRN from Pfizer Canada. The authors would like to thank all CIRN SOS surveillance monitors, as well as staff at the Canadian Center for Vaccinology (CCfV), who were instrumental in the recruitment, collection, and processing of CAP and IPD specimens. Technical assistance of the laboratory staff at the Streptococcus and Sexual Transmitted Diseases Unit of the National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC) was greatly appreciated. The authors are indebted to Pfizer Laboratories for providing access to UAD-1 and UAD-2 testing. Publisher Copyright: © 2022 The Author(s)

PY - 2022/4/20

Y1 - 2022/4/20

N2 - Objective(s): In the context of age- and risk-based pneumococcal vaccine recommendations in Canada, this study presents updated data from active surveillance of pneumococcal community acquired pneumonia (pCAP) and invasive pneumococcal disease (IPD) in hospitalized adults from 2010 to 2017. Methods: S. pneumoniae was detected using culture (blood and sputum), and urine antigen detection (UAD). Serotyping was performed with Quellung, PCR, or using the PCV13- and PPV23 (non-PCV13)-specific UADs. Laboratory results, demographic, and outcome data were categorized by age (16–49, 50–64, and 65 + ) and by disease [non-bacteremic pCAP, bacteremic pCAP, and IPD(non-CAP)]. Results: 11,129 CAP cases and 216 cases of IPD (non-CAP) were identified. Laboratory testing for S. pneumoniae was performed in 8912 CAP cases, identifying 1264 (14.2%) as pCAP. Of pCAP cases, 811 (64.1%) were non-bacteremic and 455 (35.9%) were bacteremic. Adults 65 + years represented 54.5% of non-bacteremic pCAP, 41.4% of bacteremic pCAP, and 48.6% of IPD cases. Adults 50–64 years contributed 30.3%, 33.1%, and 29.9%, respectively. In pCAP, PCV13 serotypes declined between 2010 and 2014 due to declines in serotypes 7F and 19A, then plateaued from 2015 to 2017 with persistence of serotype 3. In later study years, non-bacteremic pCAP was predominant, and PPV23 (non-PCV13) serotypes increased from 2015 to 2017, with serotypes 22F, 11A, and 9 N being most frequently identified. Compared to non-pCAP, pCAP cases were more likely to be admitted to intensive care units and require mechanical ventilation. These outcomes and mortality were more common in bacteremic pCAP and IPD, versus non-bacteremic pCAP. Conclusion(s): Along with IPD, pCAP surveillance (bacteremic and non-bacteremic) is important as their trends may differ over time. With insufficient herd protection from PCV13 childhood immunization, or use of PPV23 in adults, this study supports direct adult immunization with PCV13 or higher valency conjugate vaccines to reduce the residual burden of pCAP and IPD.

AB - Objective(s): In the context of age- and risk-based pneumococcal vaccine recommendations in Canada, this study presents updated data from active surveillance of pneumococcal community acquired pneumonia (pCAP) and invasive pneumococcal disease (IPD) in hospitalized adults from 2010 to 2017. Methods: S. pneumoniae was detected using culture (blood and sputum), and urine antigen detection (UAD). Serotyping was performed with Quellung, PCR, or using the PCV13- and PPV23 (non-PCV13)-specific UADs. Laboratory results, demographic, and outcome data were categorized by age (16–49, 50–64, and 65 + ) and by disease [non-bacteremic pCAP, bacteremic pCAP, and IPD(non-CAP)]. Results: 11,129 CAP cases and 216 cases of IPD (non-CAP) were identified. Laboratory testing for S. pneumoniae was performed in 8912 CAP cases, identifying 1264 (14.2%) as pCAP. Of pCAP cases, 811 (64.1%) were non-bacteremic and 455 (35.9%) were bacteremic. Adults 65 + years represented 54.5% of non-bacteremic pCAP, 41.4% of bacteremic pCAP, and 48.6% of IPD cases. Adults 50–64 years contributed 30.3%, 33.1%, and 29.9%, respectively. In pCAP, PCV13 serotypes declined between 2010 and 2014 due to declines in serotypes 7F and 19A, then plateaued from 2015 to 2017 with persistence of serotype 3. In later study years, non-bacteremic pCAP was predominant, and PPV23 (non-PCV13) serotypes increased from 2015 to 2017, with serotypes 22F, 11A, and 9 N being most frequently identified. Compared to non-pCAP, pCAP cases were more likely to be admitted to intensive care units and require mechanical ventilation. These outcomes and mortality were more common in bacteremic pCAP and IPD, versus non-bacteremic pCAP. Conclusion(s): Along with IPD, pCAP surveillance (bacteremic and non-bacteremic) is important as their trends may differ over time. With insufficient herd protection from PCV13 childhood immunization, or use of PPV23 in adults, this study supports direct adult immunization with PCV13 or higher valency conjugate vaccines to reduce the residual burden of pCAP and IPD.

UR - http://www.scopus.com/inward/record.url?scp=85126621723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85126621723&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2022.02.081

DO - 10.1016/j.vaccine.2022.02.081

M3 - Article

C2 - 35315326

AN - SCOPUS:85126621723

SN - 0264-410X

VL - 40

SP - 2635

EP - 2646

JO - Vaccine

JF - Vaccine

IS - 18

ER -